Updated Jul 16, 2026
Watson David O. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.65M.
David O. Watson serves as the General Counsel for Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for diseases with high unmet needs. He has been involved in various SEC filings related to the company's operations.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 7.4K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 6.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 11.9K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 56.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 32.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 56.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 56.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 28.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 28.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 28.5K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 28.5K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 41.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 41.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 50.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 10.0K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 144.5K | — | |
| 2026-01-30 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 56.0K | $0.00 | |
| 2026-01-23 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 7.8K | $21.77 | $170K |
| 2026-01-21 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 2.5K | $19.79 | $49K |
| 2026-01-15 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 5.8K | $22.19 | $128K |
David O. Watson serves as the General Counsel for Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for diseases with high unmet needs. He has been involved in various SEC filings related to the company's operations.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 10 open-market sales ($1.65M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Watson David O. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.